Andrew Bosworth

Characterising the host response to an emerging Ebola virus variant from West Africa

Personal Statement:

Andrew trained as a Biomedical Scientist in Newcastle upon Tyne before joining the Health Protection Agency at Porton Down, researching next generation Anthrax vaccines. Andrew served as a molecular virologist in the Rare & Imported Pathogens Laboratory at Porton Down, and working in Professor Roger Hewson’s laboratory engaged in the diagnosis and research of viral haemorrhagic fevers and imported viral infections.

 

Prior to commencing his Health Protection Research Unit doctoral research training, his scientific work took him to Central Asia, to North Africa and West Africa. He was awarded the medal for services in West Africa in 2015 for his diagnostic work in Guinea during the Ebola Virus Disease outbreak.

 

Andrew is now undertaking post-doctoral clinical training in Clinical Microbiology at University Hospitals, Birmingham and Bart’s School of Medicine and Dentistry in London.
          

 

Andrew Bosworth

   

Lay Summary:

West Africa was in the grips of an Ebola Virus Disease outbreak, caused by the emerging Makona variant of Ebola virus. Transcriptomics and proteomics are techniques used to study the way our bodies and cells react to infection. We used these powerful techniques to investigate the ways in which the emergent Makona variant of Ebola virus from West Africa affects the immune and inflammatory response. Infection with the Makona variant was compared with other types of Ebola virus, and other similar viruses which are thought to be less deadly, in order to identify changes in our cells that may be important in disease. We investigated the effects of Ebola virus in patients, including a unique longitudinal analysis of the way a patient’s immune system is affected by Ebola virus infection. This thesis presents evidence that the Makona variant of Ebola virus is not as unique as first believed and has helped identify the reasons that Ebola virus infection causes such severe disease in human patients.

Supervisors:

  • Julian Hiscox – NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool
  • Roger Hewson – NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Public Health England
  • Miles Carroll - NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Public Health England

Publications:

Bosworth A, Dowall SF, Garcia-Dorival I, Rickett NY, Bruce CB, Matthews DA, Fang Yeah, Aljabr W, Kenny J, Nelson C, Laws TR, Williamson ED, Stewart JP, Carroll MW, Hewson R, Hiscox JA.  A comparison of host gene expression signatures associated with infection in vitro by the Makona and Ecran (Mayinga) variants of Ebola virus.  Scientific Reports. 2017, 7, 43144
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327407/

Bosworth A, Ghabbari T, Dowall S, Varghese A, Wasfi F, Hewson R, Zhioua E, Chakroun M, Tiouiri H, BenJemaa M, Znazen A, Letaief A.  Serological evidence of exposure to Rift Valley Fever virus detected in Tunisia. New Microbes New Infections. 2016; 9, 1-7
https://www.newmicrobesnewinfections.com/article/S2052-2975(15)00091-8/abstract

Dowall SD, Bewley K, Watson RJ, Vasan SS, Ghosh C, Konai MM, Gausdal G, Lorens JB, Long J, Barclay W, Garcia-Dorival I, Hiscox J, Bosworth A, Taylor I , Easterbrook L, Pitman J, Summers S, Chan-Pesley J, Funnell S, Vipond J, Charlton S, Haldar J, Hewson R, Carroll MW. Antiviral screening of multiple compounds against Ebola Virus.  Viruses. 2016; 8(11), 277
http://www.mdpi.com/1999-4915/8/11/277

Romy Kerber, Ralf Krumkamp, Boubacar Diallo, … ,  Andrew Bosworth et al. Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015. The Journal of Infectious Diseases. 2016; 214(Suppl 3), S250-S257.
https://academic.oup.com/jid/article/214/suppl_3/S250/2388264

Dowall SD, Bosworth A, Rayner E et al: Post-exposure treatment of Ebola virus disease in Guinea pigs using EBOTAb, an ovine antibody-based therapeutic. Scientific Reports. 2016; 6.
https://www.researchgate.net/publication/305715468_Post-exposure_treatment_of_Ebola_virus_disease_in_Guinea_pigs_using_EBOTAb_an_ovine_antibody-based_therapeutic

Bukbuk DN, Dowall SD, Lewandowski K, Bosworth A et al: Serological and Virological Evidence of Crimean-Congo Haemorrhagic Fever Virus Circulation in the Human Population of Borno State, Northeastern Nigeria. PLoS Neglected Tropical Diseases. 2016; 10(12).
https://www.researchgate.net/publication/311503495_Serological_and_Virological_Evidence_of_Crimean-Congo_Haemorrhagic_Fever_Virus_Circulation_in_the_Human_Population_of_Borno_State_Northeastern_Nigeria

Stuart D. Dowall, Victoria A. Graham, Emma Rayner, Barry Atkinson, Graham Hall, Robert J. Watson, Andrew Bosworth et al: A Susceptible Mouse Model for Zika Virus Infection. PLoS Neglected Tropical Diseases. 2016; 10(5).
http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004658

Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G, Rambaut A, Hewson R, García-Dorival I, Bosworth A, et al. Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa. Nature. 2015; 524, 97-101.
https://www.nature.com/articles/nature14594

Dowall SD, Bosworth A, Watson R et al: Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. Journal of General Virology. 2015; 96(12), 3484-3492.
https://www.ncbi.nlm.nih.gov/pubmed/26459826

Dowall SD, Callan J, Antra Zeltina, Al-Abdulla I, Strecker T, Fehling SK, Krähling V, Bosworth A et al: Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. The Journal of Infectious Diseases. 2015; 213(7), 1124-1133.
https://academic.oup.com/jid/article/213/7/1124/2912152